Internal Medicine, Hematology & Oncology · Freehold, NJ
NPI
1922101161
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
495 Iron Bridge Rd, Ste 14
Freehold, NJ, 07728
Phone (732) 431-8400
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.3M
351,007 services
Medicare patients, 2024
1,254
Average age 77
Drug cost, 2024
$5.1M
1,373 prescriptions
Company payments, 2025
$3,293
From 54 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeffrey M Silberberg was code J9271 (injection, pembrolizumab, 1 mg), 25,600 times for 32 patients. In total Jeffrey M Silberberg billed 351,007 services in 155 codes, and Medicare paid $6.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 25,600 | 32 | $44.60 | $1.1M |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 21,000 | 24 | $0.87 | $18K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 17,360 | 33 | $2.36 | $41K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 17,200 | 15 | $0.06 | $950 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 16,740 | 15 | $39.07 | $654K |
| J1756 Injection, iron sucrose, 1 mg | Office | 12,600 | 26 | $0.16 | $2,017 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 12,000 | 21 | $0.11 | $1,355 |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 5,500 | 23 | $4.43 | $24K |
| J0897 Injection, denosumab, 1 mg | Office | 5,340 | 44 | $20.70 | $111K |
| J0185 Injection, aprepitant, 1 mg | Office | 5,330 | 23 | $1.36 | $7,223 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 4,800 | 46 | $15.86 | $76K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 4,060 | 29 | $6.41 | $26K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,828 | 13 | $19.54 | $75K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,398 | 88 | $0.09 | $306 |
| 36415 Venipuncture Blood Collection | Office | 3,107 | 860 | $8.64 | $27K |
By year: 2022 $4.2M for 192,563 services; 2023 $3.8M for 206,309 services; 2024 $6.3M for 351,007 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 3,107 | 860 | $8.64 | $27K |
| 85025 Blood Count | 3,089 | 838 | $7.60 | $23K |
Medicare prescription drug claims, 2024
In 2024, the drug Jeffrey M Silberberg prescribed most often to Medicare patients was Anastrozole, with 271 prescriptions and refills. In total Jeffrey M Silberberg wrote 1,373 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 271 | 751 | 74 | $5,364 |
| Hydroxyurea Generic | 93 | 245 | 31 | $2,824 |
| Eliquis Apixaban | 71 | 123 | 19 | $70K |
| Brukinsa Zanubrutinib | 61 | 61 | Under 11 | $907K |
| Ondansetron Odt Ondansetron | 59 | 59 | 41 | $809 |
| Prednisone Generic | 48 | 115 | 21 | $392 |
| Abiraterone Acetate Generic | 45 | 45 | Under 11 | $56K |
| Acyclovir Generic | 41 | 121 | 20 | $1,040 |
| Letrozole Generic | 40 | 110 | 11 | $958 |
| Jakafi Ruxolitinib Phosphate | 30 | 30 | Under 11 | $497K |
| Venclexta Venetoclax | 28 | 28 | Under 11 | $364K |
| Xarelto Rivaroxaban | 24 | 40 | Under 11 | $22K |
| Allopurinol Generic | 22 | 50 | 13 | $312 |
| Imbruvica Ibrutinib | 22 | 22 | Under 11 | $378K |
| Pantoprazole Sodium Generic | 22 | 50 | 13 | $172 |
Brand drugs: 390 claims; generic drugs: 983 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeffrey M Silberberg $3,293 ($3,293 in general payments such as food, travel and fees) from 54 companies. The largest payer was Daiichi Sankyo Inc. with $438.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 22 | $438 |
| Janssen Biotech, Inc. JNJ | 5 | $194 |
| E.R. Squibb & Sons, L.L.C. BMY | 15 | $192 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 14 | $185 |
| GlaxoSmithKline, LLC. GSK | 9 | $176 |
| Pfizer Inc. PFE | 7 | $127 |
| Gilead Sciences, Inc. GILD | 7 | $121 |
| Abbvie Inc. ABBV | 7 | $116 |
| Genentech USA, Inc. ROG.SW | 4 | $79.63 |
| Genzyme Corporation SNY | 4 | $77.93 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.